No Data
UBS Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $768
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $903
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $1,000
Regeneron Pharmaceuticals Shares Are Trading Lower After the Federal Circuit Affirmed the Denial of the Company's Motion in the Preliminary Injunction for Regeneron Pharmaceuticals V. Amgen Regarding Patent Infringement for Eylea.
Sector Update: Health Care Stocks Rise in Afternoon Trading
Sector Update: Health Care
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
